The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
Featured:
Nicolaus KrögerDuring the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Nicolaus Kröger, University Medical Center Hamburg-Eppendorf, Hamburg, DE, about allogeneic stem cell transplantation (allo-SCT). We asked, At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
Unlike autologous-SCT, allo-SCT has not become a standard of care for the treatment of MM. However, long term data exist showing that allo-SCT has the potential to be curative. At the same time, SCT-associated morbidity and mortality can be high, highlighting the importance of patient selection. Nicolaus Kröger discusses the results from several studies comparing auto-SCT with allo-SCT.